Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages
| Autor: | Jean-Damien Ricard, Mélanie Fromentin, Laurent Debarbieux, Nicolas Dufour |
|---|---|
| Přispěvatelé: | Biologie Moléculaire du Gène chez les Extrêmophiles (BMGE), Institut Pasteur [Paris], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Service de Réanimation Médico-Chirurgicale [Hôpital Louis Mourier], Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Supported, in part, by a joint research grant from both Institut Pasteur and Assistance Publique–Hôpitaux de Paris (Programme Transversal de Recherches no 417).Dr. Dufour received support for article research from the Institut Pasteur and Assistance Publique–Hôpitaux de Paris (joint research grant, recipient of a Poste d’Accueil). His institution received grant support from the Institut Pasteur (joint research grant between Assistance Publique–Hôpitaux de Paris and Institut Pasteur). Dr. Debarbieux received grant support from the National Science Center of Poland (reviewing grant application), other support from Institut National de la Recherche Agronomique (INRA) (member of a jury to evaluate candidates for permanent positions in INRA), and support for article research from the Institut Pasteur and Assistance Publique des Hôpitaux de Paris. His institution received grant support from the Assistance Publique des Hôpitaux de Paris (grant received for a joint research program between Institut Pasteur and Assistance Publique des hôpitaux de Paris). Dr. Ricard served as a board member for Covidien and received support for travel from Fisher&Paykel. Ms. Fromentin has disclosed that she does not have any potential conflicts of interest., Institut Pasteur [Paris] (IP), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Debarbieux, Laurent |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_treatment Antibiotics MESH: Pneumonia Ventilator-Associated Critical Care and Intensive Care Medicine medicine.disease_cause phage therapy 2 Mice bacteriophage Bacteriophages MESH: Animals Lung Escherichia coli Infections Mice Inbred BALB C Extraintestinal Pathogenic Escherichia coli lung infection MESH: Escherichia coli Pneumonia Ventilator-Associated Anti-Bacterial Agents 3. Good health Ceftriaxone Bronchoalveolar Lavage Fluid medicine.drug Phage therapy MESH: Pneumonia Bacterial medicine.drug_class MESH: Mice Inbred BALB C Virulence Microbiology ventilator-associated pneumonia In vivo MESH: Anti-Bacterial Agents Pneumonia Bacterial medicine Escherichia coli nosocomial infections Animals MESH: Lung MESH: Bacteriophages MESH: Mice MESH: Escherichia coli Infections business.industry MESH: Bronchoalveolar Lavage Fluid medicine.disease Virology [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology MESH: Male Disease Models Animal Pneumonia [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology MESH: Disease Models Animal business |
| Zdroj: | Critical Care Medicine Critical Care Medicine, Lippincott, Williams & Wilkins, 2015, 43 (6), pp.e190-8. ⟨10.1097/CCM.0000000000000968⟩ Critical Care Medicine, 2015, 43 (6), pp.e190-8. ⟨10.1097/CCM.0000000000000968⟩ |
| ISSN: | 0090-3493 1530-0293 |
| DOI: | 10.1097/CCM.0000000000000968⟩ |
| Popis: | Comment in: Time for tailored antimicrobials: adapted bacteriophages in the ICU [Crit Care Med. 2015]; International audience; OBJECTIVE:To study the effect of bacteriophage treatment on highly virulent extraintestinal Escherichia coli pneumonia in mice and compare it with conventional antimicrobial treatment.DESIGN:Animal investigation.SETTING:University research laboratory.SUBJECTS:Pathogen-free 8-week-old Balb/cJRj male mice.INTERVENTIONS:Two bacteriophages (536_P1 and 536_P7) were isolated from sewage using strain 536, a highly virulent extraintestinal E. coli. Their in vitro and in vivo efficacy against strain 536 and a ventilator-associated pneumonia E. coli were tested. The first group of mice were infected by intranasal instillation of bioluminescent strain 536 and received 536_P1 intranasally, ceftriaxone, or control. The second group of mice was infected with the ventilator-associated pneumonia strain and received 536_P7. Adaptation of 536_P7 to this clinical isolate was also evaluated in vitro and in vivo.MEASUREMENTS AND MAIN RESULTS:In vivo efficacy of bacteriophage and antibiotic treatment were assessed by recording bioluminescence for short-time periods and by recording body weight and survival of mice for longer periods. Both treatments improved survival compared with control (100% vs 0%), and in vivo bioluminescence recordings showed a similar rapid decrease of emitted light, suggesting prompt bacterial clearance. The majority of mice infected by the ventilator-associated pneumonia strain were not rescued by treatment with 536_P7; however, in vitro adaptation of this bacteriophage toward the ventilator-associated pneumonia strain led to isolate a variant which significantly improved in vivo treatment efficacy (animal survival increased from 20% to 75%).CONCLUSIONS:Bacteriophage treatment was as effective as antibiotherapy to provide 100% survival rate in a lethal model of highly virulent E. coli pneumonia. Adaptation of a bacteriophage is a rapid solution to improve its efficacy toward specific strains. These results suggest that phage therapy could be a promising therapeutic strategy for ventilator-associated pneumonia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|